For the past four years, Nupsala has proudly partnered with Astaria to provide equine veterinarians across the United Kingdom with access to the Alpha2Eq product. Throughout this time, Nupsala has worked closely with the veterinary profession, delivering technical support, training, and guidance to ensure best clinical outcomes.

Nupsala remains firmly committed to the principles of professional ethics, product neutrality, and unbiased clinical choice. We believe that veterinarians should be empowered to make informed decisions based on value, performance, and patient outcomes —free from commercial exclusivity or pressure.

In 2024, Nupsala was approached by Belgian company Intibio, which has developed an alternative A2M (Alpha-2-Macroglobulin) processing kit. This product introduces several technical modifications and is offered at a different price point, giving veterinarians a viable new option.

Astaria subsequently requested that Nupsala refrain from distributing the Intibio kit and sought exclusivity in the UK market. Nupsala declined this request, as it contradicts our core principles and our dedication to supporting the freedom of choice within the equine veterinary community.

As a result, Astaria has chosen to transition the Alpha2Eq product to a different UK distributor in an effort to restrict market access for the Intibio kit. Nupsala, however, welcomes this development as it enables true market competition and transparency.

Greg McGarrell, CEO of Nupsala, stated:

“Integrity is at the heart of our company, along with other core values such as: if we can do it better, we will; improving the life and welfare of the patient and our clients. I am constantly looking for new and improved innovation to help the equine vet in their role. Through this, I am happy that the equine vet has the choice to decide which technology to use. Improved technology will prevail. I urge all equine vets to discuss the options with their account manager or the Nupsala clinical team.”

The Intibio A2M kit is now available in the UK exclusively from Nupsala. It is compatible with existing centrifuge systems, and comparative studies are available upon request.

Nupsala remains dedicated to supporting equine veterinarians with ethical, innovative, and effective solutions — because choice drives progress.